A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

NCT03871348 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

77

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor terminated the study for non-safety reasons

Conditions

Metastatic Neoplasm

Interventions

DRUG: SAR441000
DRUG: Cemiplimab REGN2810

Sponsor

Sanofi

Collaborators

[object Object]